|Bid||125.00 x 900|
|Ask||168.95 x 800|
|Day's Range||160.30 - 162.75|
|52 Week Range||82.25 - 219.75|
|Beta (5Y Monthly)||1.06|
|PE Ratio (TTM)||66.89|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul 02, 2010|
|1y Target Est||N/A|
Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.
John L Higgins, Insider at Ligand Pharmaceuticals (NASDAQ:LGND), made a large insider sell on November 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Higgins sold 3,000 shares of Ligand Pharmaceuticals at a price of $160.50. The total transaction amounted to $481,500. Following the transaction, Higgins still owns 335,095 shares of the company, worth $53,065,644. Ligand Pharmaceuticals shares are trading dow
A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.